Showing results (171-180 of 203) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt, Fanny Piette, Sherene Loi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.The Lancet. Oncology|October 25, 2011
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialElisabeth Quoix, Rodryg Ramlau, Virginie Westeel, et al.The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.Pageof 21